Arjo AB (FRA:A39) Piotroski F-Score: 5 (As of Jun. 27, 2026) — 29% Below Median


FRA:A39 Arjo AB FRA:A39
72 GF Score
Price €2.21
GF Value €3.24
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Arjo AB Piotroski F-Score?

Arjo AB FRA:A39 +1.10% 72 Piotroski F-Score is 5 as of Jun. 27, 2026, which is 29% below its 10-year median of 7.00. GuruFocus rates FRA:A39 with a GF Score™ of 72/100 and a GF Value™ of €3.24 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 114 Medical Distribution companies, Arjo AB ranks better than 52.63% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Arjo AB has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Arjo AB's Piotroski F-Score or its related term are showing as below:

FRA:A39' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 7   Max: 9
Current: 5

During the past 13 years, the highest Piotroski F-Score of Arjo AB was 9. The lowest was 5. And the median was 7.

Arjo AB  (FRA:A39) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Arjo AB Piotroski F-Score Related Terms


Arjo AB Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Arjo AB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arjo AB Piotroski F-Score Chart

Arjo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 6.00 5.00 9.00 5.00

Arjo AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 8.00 7.00 5.00 5.00

FRA:A39 vs MCK, COR, CAH: Piotroski F-Score Comparison

For the Medical Distribution subindustry, Arjo AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arjo AB Piotroski F-Score vs Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Arjo AB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Arjo AB's Piotroski F-Score falls into.


FRA:A39
72GF Score
Arjo AB FRA:A39
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 8.354 + 7.363 + 6.432 + 10.027 = €32.2 Mil.
Cash Flow from Operations was 18.615 + 40.542 + 55.135 + 22.003 = €136.3 Mil.
Revenue was 243.169 + 240.527 + 258.585 + 250.48 = €992.8 Mil.
Gross Profit was 105.512 + 98.902 + 108.892 + 106.672 = €420.0 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(1397.797 + 1403.806 + 1380.806 + 1376.269 + 1436.87) / 5 = €1399.1096 Mil.
Total Assets at the begining of this year (Mar25) was €1,397.8 Mil.
Long-Term Debt & Capital Lease Obligation was €78.2 Mil.
Total Current Assets was €430.1 Mil.
Total Current Liabilities was €398.7 Mil.
Net Income was 10.63 + 6.43 + 15.127 + 8.307 = €40.5 Mil.

Revenue was 248.926 + 240.819 + 259.854 + 261.357 = €1,011.0 Mil.
Gross Profit was 108.429 + 101.031 + 116.147 + 114.11 = €439.7 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(1412.081 + 1407.718 + 1380.876 + 1414.982 + 1397.797) / 5 = €1402.6908 Mil.
Total Assets at the begining of last year (Mar24) was €1,412.1 Mil.
Long-Term Debt & Capital Lease Obligation was €72.8 Mil.
Total Current Assets was €400.1 Mil.
Total Current Liabilities was €405.2 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Arjo AB's current Net Income (TTM) was 32.2. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Arjo AB's current Cash Flow from Operations (TTM) was 136.3. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=32.176/1397.797
=0.02301908

ROA (Last Year)=Net Income/Total Assets (Mar24)
=40.494/1412.081
=0.02867683

Arjo AB's return on assets of this year was 0.02301908. Arjo AB's return on assets of last year was 0.02867683. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Arjo AB's current Net Income (TTM) was 32.2. Arjo AB's current Cash Flow from Operations (TTM) was 136.3. ==> 136.3 > 32.2 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=78.17/1399.1096
=0.05587125

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=72.756/1402.6908
=0.05186888

Arjo AB's gearing of this year was 0.05587125. Arjo AB's gearing of last year was 0.05186888. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=430.123/398.744
=1.0786946

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=400.114/405.226
=0.98738482

Arjo AB's current ratio of this year was 1.0786946. Arjo AB's current ratio of last year was 0.98738482. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Arjo AB's number of shares in issue this year was 272.37. Arjo AB's number of shares in issue last year was 272.37. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=419.978/992.761
=0.42304039

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=439.717/1010.956
=0.43495167

Arjo AB's gross margin of this year was 0.42304039. Arjo AB's gross margin of last year was 0.43495167. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=992.761/1397.797
=0.7102326

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1010.956/1412.081
=0.71593343

Arjo AB's asset turnover of this year was 0.7102326. Arjo AB's asset turnover of last year was 0.71593343. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+0+1+1+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Arjo AB has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Arjo AB (FRA:A39) has a Piotroski F-Score of 5 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Arjo AB and its competitors. This is 29% below median its historical median of 7.00. Over the past decade, Arjo AB's Piotroski F-Score has ranged from 5.00 to 9.00. According to the industry distribution chart, Arjo AB ranks #54 out of 114 companies in the Medical Distribution industry, placing it in the top 47.4%.
Is Arjo AB's Piotroski F-Score too high?
Arjo AB's current Piotroski F-Score of 5 is 29% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 9.00. The Medical Distribution industry median Piotroski F-Score is 5.00. Arjo AB's value of 5 is 0% at this industry median. Based on the distribution chart, Arjo AB ranks #54 out of 114 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Arjo AB has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's Piotroski F-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #54 out of 114 companies for Piotroski F-Score. This puts Arjo AB in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Arjo AB's value of 5 is 0% at this benchmark. Historically, Arjo AB's own Piotroski F-Score has ranged from 5.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Arjo AB has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arjo AB's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Arjo AB and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arjo AB's current Piotroski F-Score is 5, which is 29% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (FRA:A39) is currently considered Significantly Undervalued. The stock's GF Value™ is €3.24, compared to a current price of €2.21 — trading 31.7% below its estimated fair value. The current Piotroski F-Score is 5, which is 29% below median its 10-year median of 7.00 and 0% at the Medical Distribution industry median of 5.00. Arjo AB's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Arjo AB (FRA:A39), the current Piotroski F-Score is 5 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arjo AB (FRA:A39) Overvalued in 2026?

Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued. The current stock price of €2.21 is trading 31.7% below its estimated GF Value™ of €3.24. GuruFocus considers Arjo AB to be Significantly Undervalued.

Key valuation signals for FRA:A39:

  • Piotroski F-Score: 5 (29% below median its 10-year median of 7.00)
  • GF Value™: €3.24 vs. price of €2.21 (31.7% below fair value)
  • GF Score™: 72/100 with 5 warning signs
  • Industry Position: 0% at the Medical Distribution median (#54 of 114)

No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arjo AB Business Description

Address Hans Michelsensgatan 10, Box 48, Malmo, SWE, SE-201 20
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
72GF Score

Get the complete analysis for FRA:A39

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.21
Price
€3.24
GF Value